934 related articles for article (PubMed ID: 26027741)
1. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
De Mattia E; Cecchin E; Toffoli G
Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
[TBL] [Abstract][Full Text] [Related]
2. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
Cecchin E; De Mattia E; Ecca F; Toffoli G
Drug Resist Updat; 2018 Jul; 39():18-40. PubMed ID: 30075835
[TBL] [Abstract][Full Text] [Related]
3. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS; Semrad TJ
Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
[TBL] [Abstract][Full Text] [Related]
4. Personalized treatment for patients with colorectal cancer: role of biomarkers.
Duffy MJ
Biomark Med; 2015; 9(4):337-47. PubMed ID: 25808438
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.
Stiegelbauer V; Perakis S; Deutsch A; Ling H; Gerger A; Pichler M
World J Gastroenterol; 2014 Sep; 20(33):11727-35. PubMed ID: 25206276
[TBL] [Abstract][Full Text] [Related]
6. Current and advancing treatments for metastatic colorectal cancer.
Sanz-Garcia E; Grasselli J; Argiles G; Elez ME; Tabernero J
Expert Opin Biol Ther; 2016; 16(1):93-110. PubMed ID: 26549053
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment.
Bignucolo A; De Mattia E; Cecchin E; Roncato R; Toffoli G
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28708103
[TBL] [Abstract][Full Text] [Related]
9. Genetic Markers of the Host to Predict the Efficacy of Colorectal Cancer Targeted Therapy.
De Mattia E; Bignucolo A; Toffoli G; Cecchin E
Curr Med Chem; 2020; 27(25):4249-4273. PubMed ID: 31298142
[TBL] [Abstract][Full Text] [Related]
10. Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.
Rivera M; Fichtner I; Wulf-Goldenberg A; Sers C; Merk J; Patone G; Alp KM; Kanashova T; Mertins P; Hoffmann J; Stein U; Walther W
Neoplasia; 2021 Jan; 23(1):21-35. PubMed ID: 33212364
[TBL] [Abstract][Full Text] [Related]
11. Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer.
Katsila T; Juliachs M; Gregori J; Macarulla T; Villarreal L; Bardelli A; Torrance C; Elez E; Tabernero J; Villanueva J
Clin Cancer Res; 2014 Dec; 20(24):6346-56. PubMed ID: 25324142
[TBL] [Abstract][Full Text] [Related]
12. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer.
Asghar U; Hawkes E; Cunningham D
Clin Colorectal Cancer; 2010 Dec; 9(5):274-81. PubMed ID: 21208841
[TBL] [Abstract][Full Text] [Related]
13. Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab.
Rodríguez J; Viúdez A; Ponz-Sarvisé M; Gil-Aldea I; Chopitea A; García-Foncillas J; Gil-Bazo I
Crit Rev Oncol Hematol; 2010 Jun; 74(3):193-202. PubMed ID: 19700342
[TBL] [Abstract][Full Text] [Related]
14. Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer.
Song X; Shen L; Tong J; Kuang C; Zeng S; Schoen RE; Yu J; Pei H; Zhang L
Theranostics; 2020; 10(18):8098-8110. PubMed ID: 32724460
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer.
Okada Y; Miyamoto H; Goji T; Takayama T
Digestion; 2014; 89(1):18-23. PubMed ID: 24458108
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
Mitchell EP
Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
[TBL] [Abstract][Full Text] [Related]
17. Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy.
Bahrami A; Amerizadeh F; Hassanian SM; ShahidSales S; Khazaei M; Maftouh M; Ghayour-Mobarhan M; Ferns GA; Avan A
J Cell Physiol; 2018 Mar; 233(3):2193-2201. PubMed ID: 28422287
[TBL] [Abstract][Full Text] [Related]
18. [Recent developments of pharmacogenomics in the treatment of colorectal cancers].
Astier A
Ann Pharm Fr; 2010 Jul; 68(4):233-53. PubMed ID: 20637356
[TBL] [Abstract][Full Text] [Related]
19. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models.
Rosa R; Marciano R; Malapelle U; Formisano L; Nappi L; D'Amato C; D'Amato V; Damiano V; Marfè G; Del Vecchio S; Zannetti A; Greco A; De Stefano A; Carlomagno C; Veneziani BM; Troncone G; De Placido S; Bianco R
Clin Cancer Res; 2013 Jan; 19(1):138-47. PubMed ID: 23166225
[TBL] [Abstract][Full Text] [Related]
20. Molecular predictors of response to chemotherapy in colorectal cancer.
Dienstmann R; Vilar E; Tabernero J
Cancer J; 2011; 17(2):114-26. PubMed ID: 21427555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
